Clinical Trial Update: The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study [Phase 3]

View source ↗

Summary

Phase 3 trial assessing TRAfermin for neuropathic diabetic foot ulcers has completed in Northern Europe, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• Trafermin (fibroblast growth factor-2 (FGF-2))

Snippet

Sponsor: Olympus Biotech Corporation | Conditions: Diabetic Foot Ulcer of Neuropathic Origin | Phase 3 | Status: COMPLETED | Results posted: 2014-08-05